← Browse by Condition
Medical Condition

sintilimab

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT07416890 Phase 2
Recruiting

Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

Enrollment
24 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
View Trial →